Overview
Our antiviral drug screening platform enables rapid evaluation of compound efficacy against clinically relevant viruses. The assay is optimized for high-throughput analysis in 96-well formats, providing reliable preclinical data for drug discovery.

Principle

• Viruses are used to infect susceptible cells.

• Test compounds are added either before or after infection.

• Viral replication is measured by inhibition of cytopathic effect (CPE), reduction of viral titers, or through reporter assays.

Applications

• Screening novel antiviral candidates

• Preclinical validation of therapeutic compounds

• Comparative efficacy studies across virus strains

Deliverables from MIV
?? Raw and normalized data with curve fitting
?? IC?? values for compound efficacy
?? Detailed assay report with interpretation
?? Technical support for drug development programs

?

We provide services?for a wide range of viruses that are safely handled under Biosafety Level-2 (BSL-2) conditions. Our team ensures precise results with? quality standards, supporting research, vaccine development, and antiviral testing.

We provide services for the following viruses:

• Adenoviruses
• Cytomegalovirus (CMV)
• Dengue virus
• Chikungunya virus
• Herpes simplex virus (HSV-1, HSV-2)
• Influenza viruses (seasonal strains)
• Parainfluenza viruses
• Respiratory syncytial virus (RSV)
• Rubella virus
• Mumps virus
• Measles virus